What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate
Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.
You may also be interested in...
Vaccine Technologies: US FDA Isn’t Afraid Of Needle-Free Delivery, But It Takes Time To Develop, Woodcock Says
The agency is interested in alternative formulations for COVID-19 inoculations, but pushed the traditional injection presentation because it was easier to develop quickly.
The once and likely future FDA commissioner emphasizes value of randomized controlled trials, the fact that not all trials are good for people, and how decentralization and digitization are leaving people behind. Takeda exec questions if industry is being bold enough.
CRN and NPA are receptive to former FDA Commissioner Robert Califf’s potential return to the post. NPA says his previous comments on FDA’s authority is a good sign he may help act on supplement industry issues stalled within the agency in recent years.